Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer - a multinational real-world analysis

Sep 22, 2026

Multinational real-world evidence evaluates reintroduction of cisplatin-gemcitabine followed by durvalumab in advanced biliary tract cancer, aiming to clarify effectiveness and treatment feasibility outside controlled trials. The analysis compiles patient and treatment characteristics across participating healthcare centers, then assesses clinical outcomes relevant to disease control, tolerability, and continuation of therapy. By characterizing response patterns and real practice management, the study supports evidence-informed decision-making for clinicians considering reintroduction strategies in later lines of treatment.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Study Overview

Clinical Context and Rationale

Multinational Real-World Methods

Patient and Treatment Characteristics

Outcomes and Safety Focus

ORIGINAL ARTICLE Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis S. Camera1‡, A. Vogel2 , 3‡, M. Rimini1 , 4‡, M. Ikeda5, O. Abidoye6, J. Lucchetti7, L. Antonuzzo8 , 9, J. W. Kim10, F. Nichetti11, A. Saborowski2, T. Pressiani12, C. Vivaldi13, 14, I. G. Rapposelli15, F. Peeters16, C. Braconi17, D. J. Pinato18, 19, E. Tamburini20, C. Pircher21, S. Tamberi22, 23, F. Castet24, M. Verrico25, A. Parisi26, N. Couto27, H. J. Chon28, A. Martirena29, A. Lamarca29, 30, 31, M. Landriscina32, F. Finkelmeier33, E. Oneda34, A. Avallone35, E. Dell’Aquila36, L. Perkhofer37, 38, I. H. Kim39 , V. Formica40 , [C. M. de](C. M. de) Sousa Pinto41 , I. Garajova42 , B. Kang28 , S. Corallo43 , E. Fenocchio44 , G. Farinea45 , A. Pastorino46, A. Diana47, Y. Changhoon48, M. Schirripa49, M. G. Rodriquenz50, M. Scartozzi51, L. Zumstein52, M. Ghidini53, G. W. Prager54, G. Aprile55, G. P. Spinelli56, S. Yung-Yeh57 , 58, S. L. Chan59, E. Warmington18 , 19, A. Lancianese26, T. Satake5, T. S. L. Bekaii-Saab6, G. Giordano32, D. Lavacchi8 , 9, L. Passeri1, M. Ferrara1, F. Bozzarelli12, M. Persano1, G. Masi13, 14, R. Balsano12, 61, M. Niger21, S. Rimassa12, 61∗§ & A. Casadei-Gardini1 , 4∗§ Rossari1, F. Lo Prinzi60, M. Kang10, A. A. Prete20, Lonardi11, F. Salani13, 14 §, L. Fornaro13 §, 1Medical Oncology Department, IRCCS San Raffaele Hospital, Milan, Italy; 2Department of Gastroenterology, Hepatology, Infectious Disease and Endocrinology, Hannover Medical School, Hannover, Germany; 3Long Family Chair in Liver Cancer Research, Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Schwartz Reisman Liver Research Centre, Toronto, Canada; 4Vita-Salute San Raffaele University, Milan; 5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan; 6Department of Internal Medicine, Mayo Clinic, Phoenix, USA; 7Fondazione Policlinico Universitario Campus Bio-Medico, Roma; 8Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; 9Department of Experimental and Clinical Medicine, University of Florence, Florence; 10Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Republic of Korea; 11Oncology 1 Unit, Department of Medical Oncology, Veneto Institute of Oncology IOV — IRCCS, Padua, Italy; 12Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan; 13Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; 14Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa; 15Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST)“Dino Amadori”, Meldola; 16Digestive Oncology, University Hospitals Leuven, Leuven, Belgium; 17University of Glasgow (School of Cancer Sciences), Beatson West of Scotland Centre, CRUK Scotland Centre, Glasgow; 18Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; 19Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara; 20Department of Oncology and Palliative Care, Cardinale G. Panico, Tricase City Hospital, Tricase; 21Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; 22Santa Maria Delle Croci Hospital, AUSL Romagna, Ravenna; 23Department of DIMEC, University of Bologna, Bologna; 24Upper Gastrointestinal and Endocrine Tumor Unit, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona, Spain; 25UOC Oncologia A, Department of Hematology, Oncology and Dermatology, Policlinico Umberto I, Sapienza University of Rome, Rome; 26Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle

FAQs

What is the document about?

It reports a multinational real-world analysis of reintroducing cisplatin-gemcitabine with durvalumab for advanced biliary tract cancer.

Why is a real-world analysis used here?

To describe how the reintroduction approach performs in routine clinical practice across multiple centers, complementing trial evidence.

What does the study assess?

It focuses on patient and treatment characteristics and evaluates key clinical outcomes tied to effectiveness and tolerability of the approach.

Sep 22, 2026

Upload by Guten tag